

Opioid Overutilization Prevention and Opioid Use Disorder Treatment Programs

Quick Reference Guide

Concurrent Drug Utilization Review (cDUR) and Point of Sale Programs	
These programs use our pharmacy claims processing to screen prescriptions at point-of-sale for possible inappropriate drug prescribing, utilization and safety concerns.	
Cumulative morphine milligram equivalents (MME) Dose	<ul style="list-style-type: none"> Cumulative point of sale dosage limit for all opioid products over MME 90 Requires intervention from dispensing pharmacist to determine if therapy is medically appropriate
Drug-Drug Interaction – Opioids + Drugs to Treat Opioid Use Disorder (OUD)	<ul style="list-style-type: none"> Opioid claim will deny if a member has filled a drug to treat OUD within the past 30 days Edit does not impede access to the treatment for OUD Dispensing pharmacist can override the error if, in their professional judgment, the therapy is medically appropriate
Maximum Acetaminophen Dosing	<ul style="list-style-type: none"> Combination opioids plus acetaminophen (APAP) limit Point of sale quantity limit Prevents doses of APAP greater than 4 grams per day
Duplicative Therapy Edit – Long Acting Opioids	<ul style="list-style-type: none"> Point of sale edit if member is taking more than one long acting opioid Requires intervention from dispensing pharmacist to determine if therapy is medically appropriate
Drug-Drug Interaction – Opioids + Benzodiazepines	<ul style="list-style-type: none"> Point of sale edit if member is taking opioids and benzodiazepines concurrently Requires intervention from dispensing pharmacist to determine if therapy is medically appropriate and to educate patient on risk of taking these medications together
Utilization Management Programs	
These programs allow for the evaluation of a patient's drug therapy before medication is dispensed and help ensure safe, appropriate and cost-effective drug utilization.	
Prior Authorization/Medical Necessity	Prior Authorization to ensure appropriate use and medical necessity <ul style="list-style-type: none"> Doses above formulary quantity limits on all opioid products Transmucosal Fentanyl Products (High risk products) Most long acting opioids Pediatric Tramadol and Codeine
Access to Medication-Assisted Treatment	<ul style="list-style-type: none"> No Prior Authorization for preferred products (i.e. generic buprenorphine/naloxone sublingual tablet, Suboxone® sublingual film) Prior Authorization for higher cost products to ensure appropriate use
Access to Overdose Prevention Medication (naloxone)	<ul style="list-style-type: none"> No prior authorization is required for preferred naloxone products (Generic naloxone injection and Narcan® Nasal Spray) No quantity limit on generic; Quantity limit of 2 on brand Narcan® product
7 Day First Prescription Fill Limit for Patients New to Therapy	<ul style="list-style-type: none"> 7 day dispensing limits for opioids for opioid naïve members

Retrospective Drug Utilization Review (rDUR) Programs

These programs review drug therapies after the patient has received the medications to screen for appropriate use and over utilization.

DUR Program via Medication Therapy Management (MTM) program	<ul style="list-style-type: none"> • Identify potential inappropriate opioid utilization or members at risk for adverse events due to opioids • Pharmacists work directly with providers and can help develop taper plans if needed
MME 90 Member and Provider Letters	<ul style="list-style-type: none"> • Targeted letters to members and their prescribers who are on chronic opiates with doses great than MME-90 • Letters to providers also include information of benzodiazepine fill history

Other Programs

Fraud/Waste/Abuse Monitoring and Detection	<ul style="list-style-type: none"> • Retrospective controlled substance claims analysis • Identifies outlier opioid prescribers and members for further investigation
Case and Disease Management for Chronic Pain	<ul style="list-style-type: none"> • Run by the Care Management Program • Patients can self-enroll or be referred into the program
Pathway To Treat- Persistent, Non-Malignant Pain	<ul style="list-style-type: none"> • Educational material sent to prescribers and available on plans website • Includes information on safe prescribing practices for opioids, non-opioid options, naloxone use and how to taper opioids
Substance Use Disorder Helpline	<ul style="list-style-type: none"> • 24/7 helpline (855-780-5955) for members or caregivers staffed by licensed behavioral health providers